Zealand Pharma A/s

Universitéde Montreal

Pharmacopeia Inc.

Merck Sharp + Dohme B.v.

Andrew Roughton

Jennifer L Hickey

Manuel Perez Vazquez

Adam Paul Kafal

M Monzur Morshed

Sai Kumar Chakka

James Gillard

Marc-André Poupart

Gaoqiang Yang

Mohammed Monzur Morshed

Narendrakumar B Patel

Koc-Kan Ho

Michael H Ohlmeyer

Nasrin Ansari

David Jonathan Bennett

Michelle Lee Morris

Irina Neagu

Andrew Cooke

Yajing Rong

Jui-Hsiang Chan

Andrew Stanley Edwards

Narendra Patel

Monzur M Morshed

There is described herein, multimers comprising a plurality of compounds covalently linked together, the compounds independently being of formula (I).

Cyclic peptides multimers targeting α4β7 integrin

Cyclic peptides multimers targeting &#x3b1;-4-&#x3b2;-7 integrin

There is described herein antagonists of &#x3b1;4&#x3b2;7 integrin, and more particularly cyclic peptide antagonists, such as compounds of formula (I).

Homodetic cyclic peptides targeting alpha-4-beta-7 integrin

Cyclic peptides multimers targeting alpha-4-beta-7 integrin

There is described herein antagonists of &#x3b1;4&#x3b2;7 integrin, and more particularly to cyclic peptide antagonists. Accordingly, there is described herein a compound of formula (I) wherein R, R, R, R, R, R, Rand Rare various substituents; stereocentres 1*, 2* and 3* are each independently selected from R and S; n is 1, 2, 3, or 4 and where n is 2-4, Z is an amino terminus of an amino acid; &#x2014;C&#x2550;O&#x2014; adjacent L is the carboxy terminus of an amino acid; and L along with Z and &#x2014;C&#x2550;O&#x2014; is a peptide. 

Cyclic peptides targeting alpha-4-beta-7 integrin

There is described herein use of a compound of formula (I) below to make cyclic peptides. 

Fragment synthesis of substituted cyclic peptides

The present invention relates to 1-(4-ureidobenzoyl)piperazine derivatives having the general Formula I (We bring to your attention that formula I is not provided on this electronic version as it is provided in the abstract of the paper copy) Wherein Ris (C)alkyl, (C)cycloalkyl or (C)cycloalkyl(C)alkyl, each of which may be substituted by hydroxy, cyano or halogen; Rrepresents 1 or 2 optional halogens; Ris (C)alkyl, (C)cycloalkyl or (C)cycloalkyl(C)alkyl, each of which may be substituted by one or more halogens; A represents a heteroaryl ring system comprising 1-3 heteroatoms selected from N, O and S, which ring system is 5- or 6-membered when X is C, and 5-membered when X is N; n is 1 or 2; or a pharmaceutically acceptable salt thereof; to pharmaceutical compositions comprising the same, and to the use of a these 1-(4-ureidobenzoyl)piperazine derivatives for the manufacture of a medicament for treating or preventing atherosclerosis and related disorders associated with cholesterol and bile acids transport and metabolism. 

1-(4-ureidobenzoyl)piperazine derivatives

Growing community of inventors

Port Hope, Canada

Andrew Roughton